The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells

Current Opinion in Immunology

Volumn 19, Issue 6, 2007, Pages 665-673

  Lin, Amy Erica ^a,b   Mak, Tak W ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIGASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; CELL FUNCTION; CLONAL ANERGY; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; MEDICAL RESEARCH; MOLECULE; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; UBIQUITINATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CLONAL ANERGY; HUMANS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; UBIQUITIN-PROTEIN LIGASES;

EID: 36849043810     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2007.10.002     Document Type: Review

References (69)

1. Hershko A., and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67 (1998) 425-479
2. Pickart C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem 70 (2001) 503-533
3. Wang J., and Maldonado M.A. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 3 (2006) 255-261. This article reviews the role of ubiquitination and the proteasome in autoimmunity.
4. Mueller D.L. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 5 (2004) 883-890. This article reviews the role of ubiquitination and E3 ligases in T cell homeostasis.
5. Fang N., Fang D., Wang H.Y., Altman A., and Liu Y.C. Regulation of immune responses by E3 ubiquitin-protein ligases. Curr Dir Autoimmun 5 (2002) 161-175. This article reviews the role of ubiquitination and E3 ligases in T cell homeostasis and autoimmunity including Cbl-b, GRAIL, and Itch.
6. Gallegos A.M., and Bevan M.J. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med 200 (2004) 1039-1049
7. Gallegos A.M., and Bevan M.J. Central tolerance: good but imperfect. Immunol Rev 209 (2006) 290-296
8. Goodnow C.C., Sprent J., Fazekas de St Groth B., and Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435 (2005) 590-597
9. Li L., and Boussiotis V.A. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. J Mol Med 84 (2006) 887-899
10. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. The Finnish-German APECED Consortium. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Nat Genet 17 (1997) 399-403
11. Devoss J.J., and Anderson MS. Lessons on immune tolerance from the monogenic disease APS1. Curr Opin Genet Dev 17 (2007) 193-200
12. Ramsey C., Winqvist O., Puhakka L., Halonen M., Moro A., Kampe O., Eskelin P., Pelto-Huikko M., and Peltonen L. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet 11 (2002) 397-409
13. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., von Boehmer H., Bronson R., Dierich A., Benoist C., et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 298 (2002) 1395-1401
14. Holmdahl R. Aire-ing self antigen variability and tolerance. Eur J Immunol 37 (2007) 598-601
15. Cheng M.H., Shum A.K., and Anderson M.S. What's new in the Aire?. Trends Immunol 28 (2007) 321-327
16. Uchida D., Hatakeyama S., Matsushima A., Han H., Ishido S., Hotta H., Kudoh J., Shimizu N., Doucas V., Nakayama K.I., et al. AIRE functions as an E3 ubiquitin ligase. J Exp Med 199 (2004) 167-172
17. Bottomley M.J., Stier G., Pennacchini D., Legube G., Simon B., Akhtar A., Sattler M., and Musco G. NMR structure of the first PHD finger of autoimmune regulator protein (AIRE1). Insights into autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) disease. J Biol Chem 280 (2005) 11505-11512. This article describes the crystal structure of the PHD1 domain of AIRE and confirms its structural similarity to a RING finger domain. Disease-associated point mutations in the PHD1 domain compromise the protein fold responsible for zinc binding, thereby disrupting AIRE function. Interestingly, this group shows that the PHD1 domain is not capable of autoubiquitination.
18. Akiyoshi H., Hatakeyama S., Pitkanen J., Mouri Y., Doucas V., Kudoh J., Tsurugaya K., Uchida D., Matsushima A., Oshikawa K., et al. Subcellular expression of autoimmune regulator is organized in a spatiotemporal manner. J Biol Chem 279 (2004) 33984-33991
19. Adamson K.A., Pearce S.H., Lamb J.R., Seckl J.R., and Howie S.E. A comparative study of mRNA and protein expression of the autoimmune regulator gene (Aire) in embryonic and adult murine tissues. J Pathol 202 (2004) 180-187
20. Ramsey C., Hassler S., Marits P., Kampe O., Surh C.D., Peltonen L., and Winqvist O. Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator. Eur J Immunol 36 (2006) 305-317
21. Aschenbrenner K., D'Cruz L.M., Vollmann E.H., Hinterberger M., Emmerich J., Swee L.K., Rolink A., and Klein L. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 8 (2007) 351-358
22. Bachmaier K., Krawczyk C., Kozieradzki I., Kong Y.Y., Sasaki T., Oliveira-dos-Santos A., Mariathasan S., Bouchard D., Wakeham A., Itie A., et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403 (2000) 211-216
23. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.J., Jang I.K., Gutkind J.S., Shevach E., and Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403 (2000) 216-220
24. Krawczyk C., Bachmaier K., Sasaki T., Jones R.G., Snapper S.B., Bouchard D., Kozieradzki I., Ohashi P.S., Alt F.W., and Penninger J.M. Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity 13 (2000) 463-473
25. Bergholdt R., Taxvig C., Eising S., Nerup J., and Pociot F. CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J Leukoc Biol 77 (2005) 579-585
26. Kitaura Y., Jang I.K., Wang Y., Han Y.C., Inazu T., Cadera E.J., Schlissel M., Hardy R.R., and Gu H. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 26 (2007) 567-578
27. Chiang J.Y., Jang I.K., Hodes R., and Gu H. Ablation of Cbl-b provides protection against transplanted and spontaneous tumors. J Clin Invest 117 (2007) 1029-1036
28. Bachmaier K., Toya S., Gao X., Triantafillou T., Garrean S., Park G.Y., Frey R.S., Vogel S., Minshall R., Christman J.W., et al. E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury. Nat Med 13 (2007) 920-926
29. Loeser S., Loser K., Bijker M.S., Rangachari M., van der Burg S.H., Wada T., Beissert S., Melief C.J., and Penninger J.M. Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells. J Exp Med 204 (2007) 879-891
30. Fang D., and Liu Y.C. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2 (2001) 870-875
31. Fang D., Wang H.Y., Fang N., Altman Y., Elly C., and Liu Y.C. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem 276 (2001) 4872-4878
32. Wohlfert E.A., Callahan M.K., and Clark R.B. Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. J Immunol 173 (2004) 1059-1065
33. Wohlfert E.A., Gorelik L., Mittler R., Flavell R.A., and Clark R.B. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol 176 (2006) 1316-1320
34. Lomaga M.A., Henderson J.T., Elia A.J., Robertson J., Noyce R.S., Yeh W.C., and Mak T.W. Tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS. J Neurosci 20 (2000) 7384-7393
35. Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., Morony S., Capparelli C., Van G., Kaufman S., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13 (1999) 1015-1024
36. Kobayashi T., Walsh M.C., and Choi Y. The role of TRAF6 in signal transduction and the immune response. Microbes Infect 6 (2004) 1333-1338
37. Sun L., Deng L., Ea C.K., Xia Z.P., and Chen Z.J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14 (2004) 289-301
38. Akiyama T., Maeda S., Yamane S., Ogino K., Kasai M., Kajiura F., Matsumoto M., and Inoue J. Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science 308 (2005) 248-251
39. Kobayashi T., Walsh P.T., Walsh M.C., Speirs K.M., Chiffoleau E., King C.G., Hancock W.W., Caamano J.H., Hunter C.A., Scott P., et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 19 (2003) 353-363
40. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., Pickart C., and Chen Z.J. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103 (2000) 351-361
41. Thomas R. The TRAF6-NF kappa B signaling pathway in autoimmunity: not just inflammation. Arthritis Res Ther 7 (2005) 170-173
42. Chiffoleau E., Kobayashi T., Walsh M.C., King C.G., Walsh P.T., Hancock W.W., Choi Y., and Turka L.A. TNF receptor-associated factor 6 deficiency during hemopoiesis induces Th2-polarized inflammatory disease. J Immunol 171 (2003) 5751-5759
43. King C.G., Kobayashi T., Cejas P.J., Kim T., Yoon K., Kim G.K., Chiffoleau E., Hickman S.P., Walsh P.T., Turka L.A., et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 12 (2006) 1088-1092. This article reports on a murine conditional deletion of Traf6 used to study TRAF6's role in T cell homeostasis. These mutants develop severe T cell-mediated autoimmune disease, suggesting a novel role for TRAF6 in peripheral tolerance and autoimmunity.
44. Borlado L.R., Redondo C., Alvarez B., Jimenez C., Criado L.M., Flores J., Marcos M.A., Martinez A.C., Balomenos D., and Carrera A.C. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 14 (2000) 895-903
45. Rathmell J.C., Elstrom R.L., Cinalli R.M., and Thompson C.B. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur J Immunol 33 (2003) 2223-2232
46. Parsons M.J., Jones R.G., Tsao M.S., Odermatt B., Ohashi P.S., and Woodgett J.R. Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. J Immunol 167 (2001) 42-48
47. Anandasabapathy N., Ford G.S., Bloom D., Holness C., Paragas V., Seroogy C., Skrenta H., Hollenhorst M., Fathman C.G., and Soares L. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18 (2003) 535-547
48. Seroogy C.M., Soares L., Ranheim E.A., Su L., Holness C., Bloom D., and Fathman C.G. The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol 173 (2004) 79-85
49. MacKenzie D.A., Schartner J., Lin J., Timmel A., Jennens-Clough M., Fathman C.G., and Seroogy C.M. GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype. J Biol Chem 282 (2007) 9696-9702
50. Su L., Lineberry N., Huh Y., Soares L., and Fathman C.G. A novel E3 ubiquitin ligase substrate screen identifies Rho guanine dissociation inhibitor as a substrate of gene related to anergy in lymphocytes. J Immunol 177 (2006) 7559-7566. This article describes a novel prokaryotic method that can be used to screen for E3 ligase substrates. RhoGDIα and β are identified as the first known substrates of the E3 ligase GRAIL, linking T cell anergy to alterations in the actin cytoskeleton.
51. Perry W.L., Hustad C.M., Swing D.A., O'Sullivan T.N., Jenkins N.A., and Copeland N.G. The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat Genet 18 (1998) 143-146
52. Fang D., Elly C., Gao B., Fang N., Altman Y., Joazeiro C., Hunter T., Copeland N., Jenkins N., and Liu Y.C. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat Immunol 3 (2002) 281-287
53. Liu YC. The E3 ubiquitin ligase Itch in T cell activation, differentiation, and tolerance. Semin Immunol 19 (2007) 197-205. This article reviews the phenotype of Itch-deficient mice, as well as the role of the E3 ligase function of Itch in T cell functions, tolerance, and autoimmunity.
54. Jolliffe C.N., Harvey K.F., Haines B.P., Parasivam G., and Kumar S. Identification of multiple proteins expressed in murine embryos as binding partners for the WW domains of the ubiquitin-protein ligase Nedd4. Biochem J 351 Pt 3 (2000) 557-565
55. Harvey K.F., Shearwin-Whyatt L.M., Fotia A., Parton R.G., and Kumar S. N4WBP5, a potential target for ubiquitination by the Nedd4 family of proteins, is a novel Golgi-associated protein. J Biol Chem 277 (2002) 9307-9317
56. -/- mice. Ndfip1 was first identified as binding partner for another E3 ligase, Nedd4.
57. Rossi M., Aqeilan R.I., Neale M., Candi E., Salomoni P., Knight R.A., Croce C.M., and Melino G. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci U S A 103 (2006) 12753-12758
58. Rossi M., De Laurenzi V., Munarriz E., Green D.R., Liu Y.C., Vousden K.H., Cesareni G., and Melino G. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24 (2005) 836-848
59. Chang L., Kamata H., Solinas G., Luo J.L., Maeda S., Venuprasad K., Liu Y.C., and Karin M. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124 (2006) 601-613
60. Vinuesa C.G., Cook M.C., Angelucci C., Athanasopoulos V., Rui L., Hill K.M., Yu D., Domaschenz H., Whittle B., Lambe T., et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435 (2005) 452-458. The E3 ligase Roquin was isolated in this systematic screen of the mouse genome designed to identify novel single genes involved in autoimmunity. In the absence of Roquin, mRNAs for ICOS and RANTES (among other molecules) are upregulated. It is proposed that Roquin binds to RNA-protein complexes to alter post-transcriptional protein expression, representing a unique method of E3 ligase-mediated regulation.
61. Jeon M.S., Atfield A., Venuprasad K., Krawczyk C., Sarao R., Elly C., Yang C., Arya S., Bachmaier K., Su L., et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21 (2004) 167-177
62. Heissmeyer V., Macian F., Varma R., Im S.H., Garcia-Cozar F., Horton H.F., Byrne M.C., Feske S., Venuprasad K., Gu H., et al. A molecular dissection of lymphocyte unresponsiveness induced by sustained calcium signalling. Novartis Found Symp 267 (2005) 165-174
63. Heissmeyer V., Macian F., Im S.H., Varma R., Feske S., Venuprasad K., Gu H., Liu Y.C., Dustin M.L., and Rao A. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 5 (2004) 255-265. This article describes the signaling events in T cell anergy. The E3 ligases Cbl-b, Itch, GRAIL, and Tsg101 are upregulated upon sustained calcium-calcineurin-induced T cell anergy and coordinate in function to compromise TCR-mediated signaling.
64. Berg-Brown N.N., Gronski M.A., Jones R.G., Elford A.R., Deenick E.K., Odermatt B., Littman D.R., and Ohashi P.S. PKCtheta signals activation versus tolerance in vivo. J Exp Med 199 (2004) 743-752
65. Chang X., Chen L., Wen J., Godfrey V.L., Qiao G., Hussien Y., Zhang J., and Gao J.X. Foxp3 controls autoreactive T cell activation through transcriptional regulation of early growth response genes and E3 ubiquitin ligase genes, independently of thymic selection. Clin Immunol 121 (2006) 274-285
66. Richardson P.G., Mitsiades C., Hideshima T., and Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57 (2006) 33-47
67. Mattingly L.H., Gault R.A., and Murphy W.J. Use of systemic proteasome inhibition as an immune-modulating agent in disease. Endocr Metab Immune Disord Drug Targets 7 (2007) 29-34
68. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossart P. The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 26 (2006) 487-498
69. Nencioni A., Grunebach F., Patrone F., Ballestrero A., and Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 21 (2007) 30-36. This article reviews the use of proteasome inhibitors as effective anticancer therapeutics and potential antiautoimmune therapeutics. The mechanism of proteasome inhibitor action is not well understood, particularly with respect to autoimmune and inflammatory disorders. Current theories are discussed.